In vivo hcv resistance to anti-viral inhibitors
OwnerSteven W. Ludmerer, Donald J. Graham +2inventors
InventorsSteven W. Ludmerer, Donald J. Graham, David B. Olsen, Warren E. Glaab
Life of this patent
Estimating the term…
Abstract
HCV mutations emerged in chimpanzees treated with a N5B polymerase inhibitor (Compound A) or a NS3 protease inhibitor (Compound B). Short term treatment with Compound A was followed by the initial emergence of an HCV with a S282T polymerase mutation following treatment. Short term treatment with Compound B selected for HCV with a R155K or D168T protease mutation.
Claims14
A method of determining the existence of a hepatitis C virus (HCV) genotype resistant to a HCV protease inhibitor or HCV polymerase inhibitor comprising the steps of:
- a) removing HCV nucleic acid or polypeptide from a patient;
- and
- b) determining whether HCV present in said patient comprises at least one amino acid substitution in:
- i) position 282 of NS5B;
- ii) position 155 of NS3;
- and
- iii) position 168 of NS3,
- wherein one or more amino acid substitutions indicates resistance.
A nucleic acid sequence selected from the group consisting of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16 and SEQ ID NO:17.
Dependencies are inferred from the claim text.